Carillon Tower Advisers’s Blueprint Medicines BPMC Stock Holding History

Carillon Tower Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$37.1M	Sell	330,384 -34,848	-10%	-$3.67M	0.23%	135
2020 Q3	$22.9M	Sell	365,232 -41,541	-10%	-$3.2M	0.3%	110
2020 Q2	$31.7M	Hold	406,773	–	–	0.24%	131
2020 Q1	$23.2M	Sell	406,773 -159,393	-28%	-$10.3M	0.23%	152
2019 Q4	$45.4M	Hold	566,166	–	–	0.3%	111
2019 Q3	$41.6M	Hold	566,166	–	–	0.29%	127
2019 Q2	$53.4M	Hold	566,166	–	–	0.37%	91
2019 Q1	$45.3M	Hold	566,166	–	–	0.32%	114
2018 Q4	$30.5M	Hold	566,166	–	–	0.26%	153
2018 Q3	$44.2M	Buy	+566,166	New	+$39.3M	0.32%	118

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Carillon Tower Advisers's BPMC Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Blueprint Medicines (BPMC) stake by 9.5% in Q4 2020, selling an estimated $3.67M and leaving 330,384 shares worth $37.1M. The position accounts for 0.23% of the portfolio, ranked #135.

Carillon Tower Advisers first reported a position in BPMC in Q3 2018 and has held it in 10 quarters since. The position peaked at $53.4M in Q2 2019. 279 funds tracked by Wall St. Rank hold BPMC as of Q4 2020.

Carillon Tower Advisers held 330,384 shares of Blueprint Medicines worth $37.1M as of Q4 2020.
Carillon Tower Advisers sold 34,848 Blueprint Medicines shares in Q4 2020, an estimated $3.67M.
Blueprint Medicines made up 0.23% of Carillon Tower Advisers's portfolio in Q4 2020, its #135 holding.
Carillon Tower Advisers first reported a position in Blueprint Medicines in Q3 2018 and has held it in 10 quarters since.
Carillon Tower Advisers's Blueprint Medicines position peaked at $53.4M in Q2 2019.
279 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.